Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 4 | The Journal of Headache and Pain

Fig. 4

From: The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature

Fig. 4

Forest plots of the primary efficacy outcomes. (a) pain freedom at 2 hours between zavegepant and the placebo. (b) freedom from MBS at 2 hours between the zavegepant and the placebo. (c) pain freedom at 2 hours between the zavegepant and the oral calcitonin gene-related peptide (CGRP) receptor antagonists. (d) freedom from MBS at 2 hours between the zavegepant and the oral CGRP receptor antagonists

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us